Novartis AG Receives Consensus Recommendation of “Hold” from Brokerages (NYSE:NVS)
Shares of Novartis AG (NYSE:NVS) have earned an average recommendation of “Hold” from the eight ratings firms that are presently covering the stock, AnalystRatingsNetwork reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $93.67.
Novartis AG (NYSE:NVS) opened at 86.94 on Monday. Novartis AG has a 52-week low of $72.15 and a 52-week high of $91.66. The stock has a 50-day moving average of $89.73 and a 200-day moving average of $85.6. The company has a market cap of $210.9 billion and a P/E ratio of 22.46.
Novartis AG (NYSE:NVS) last announced its earnings results on Thursday, July 17th. The company reported $1.36 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.36. The company had revenue of $14.64 billion for the quarter, compared to the consensus estimate of $14.83 billion. During the same quarter in the previous year, the company posted $1.30 earnings per share. The company’s revenue for the quarter was up 1.0% on a year-over-year basis. On average, analysts predict that Novartis AG will post $5.14 earnings per share for the current fiscal year.
NVS has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of Novartis AG in a research note on Friday, July 25th. They now have a $94.00 price target on the stock. Separately, analysts at Barclays upgraded shares of Novartis AG from an “underweight” rating to an “equal weight” rating in a research note on Monday, June 9th. Finally, analysts at Leerink Swann raised their price target on shares of Novartis AG from $93.00 to $104.00 in a research note on Wednesday, May 28th. They now have an “outperform” rating on the stock.
Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.